Negative Points

• Sarepta Therapeutics Inc ( NASDAQ:SRPT ) narrowed its 2026 total net product revenue guidance to $1.2 billion to $1.3 billion, with the midpoint being the appropriate reference, reflecting a trend toward the lower end of the original range.

• Elevidus revenue in the second half of 2026 is expected to be modestly lower than the first half, with third-quarter revenue expected to trend lower than Q2 due to the timing of patient conversions.

• The company faces concerns regarding Elevidus adoption and potential competition on the horizon for exon skipping treatments, which could impact future market share.

• The company recorded a $39 million litigation contingency charge in the quarter to potentially resolve certain outstanding patent claims.

• The ENDEAVOR Cohort 8 data, which is critical for the non-ambulatory Elevidus indication and the LGMD program, has been delayed to the first quarter of 2027, later than initially expected.

• Total revenues decreased 34% year-over-year in the second quarter, driven primarily by lower Elevidus demand.

Q & A Highlights

Q: What excites you most about the pipeline, specifically regarding the Arrowhead products and what Cohort 8 could do for the Elevidys franchise? A: Michael Severino (CEO) expressed excitement about both areas. He highlighted the potential for Cohort 8 data on prophylactic sirolimus to improve the benefit-risk profile in the non-ambulatory population. However, he emphasized the siRNA programs (SRP-1001 for FSHD and SRP-1003 for DM1) as having "tremendous potential," citing the high predictive power of preclinical models in this space, the unambiguous biology driving the conditions, and the strong early clinical data showing dose-dependent increases in muscle concentration without dose-limiting toxicities.

Q: How are you thinking about the potential separation of the DMD pipeline and the DM1/FSHD programs, given investor interest in underwriting the DMD pipeline risk? A: Michael Severino (CEO) stated that the two areas are highly synergistic. He noted that the DMD portfolio is a "real asset" with solid, stable, and durable performance, and that the revenue generated from these products is what funds the earlier-stage siRNA pipeline. He views them as complementary, with upcoming data readouts expected to clarify the long-term role of both the DMD portfolio and the siRNA pipeline.

Q: Can you provide more color on the metrics beyond start forms that support deeper Elevidys penetration, and how might you leverage these efforts to support non-ambulatory use if it's eventually added back to the label? A: Patrick Moss (Chief Commercial Officer) noted that enrollment form activity has stabilized and improved, with returning sites re-engaging and new sites showing interest. He highlighted a directional alignment between HCP engagement and enrollment form submission, with forms often following sales team interactions within 30 days. This signals that commercial initiatives are taking hold and strengthening the patient pipeline, though revenue contribution will take time.

Q: Regarding the regulatory strategy for the siRNA programs, do you plan to pursue accelerated approval or full approval for both indications, and what do you envision the primary endpoint to be? A: Louise Rodino-Klapac (President of R&D and Technical Operations) stated that for both FSHD and DM1, the company has the ability to apply for both accelerated and traditional approval, depending on the regulatory framework, landscape, and data generated at the time. The MAD study readout will help inform the choice of outcomes for the Phase 3 trial, and the decision will be data-driven, considering the competitive landscape and discussions with regulators.

Q: Can you clarify the time lag to revenue for Elevidys? Does the quarter-over-quarter increase in demand imply a longer time to fill than the previously indicated five to six months? A: Michael Severino (CEO) clarified that the time lag between enrollment forms and revenue is generally about six months, with some variability. He confirmed that the improving enrollment forms seen now will translate into revenue meaningfully in 2027, consistent with the stated timeline. Patrick Moss (Chief Commercial Officer) added that the company continues to use the six-month enrollment form to infusion assumption for planning.

Q: With the DM1 and FSHD data approaching, what disease characteristics make a target particularly well-suited for the Alpha-V beta-6 delivery platform, and what additional muscle diseases could become attractive expansion opportunities? A: Louise Rodino-Klapac (President of R&D and Technical Operations) explained that the Alpha-V beta-6 targeting ligand was selected for its wide distribution across muscle and high receptor availability, leading to high muscle concentration. The platform is well-suited for muscle diseases with widespread need and clear pathological roles driven by toxic gain-of-function mRNA or proteins, such as DMPK in DM1 and DUX4 in FSHD. The combination of efficient delivery and potent siRNA knockdown makes the platform attractive for expansion into other muscle diseases.

Q: On the expense side, you've lowered OpEx guidance. Is there any further wiggle room, and how might the Elevidys commercial efforts and competitive dynamics for exon skippers influence long-term OpEx? A: Ryan Wong (Chief Financial Officer) stated that the company is comfortable in the $800 million to $900 million OpEx range, which allows for funding commercial initiatives and advancing the pipeline. He noted that despite acknowledging competitors, the company sees high value in both exon skipping and gene therapy programs and will continue to invest. He emphasized a prudent approach to capital allocation, focusing on science with the highest probability of success and long-term value generation.

Q: For the next SRP-1001 and SRP-1003 updates, what quantitative benchmarks does each program need to clear to justify pivotal advancement rather than continued exploration? A: Louise Rodino-Klapac (President of R&D and Technical Operations) stated that the company is looking for the ability to dose escalate safely to a dose appropriate for Phase 3, with very strong muscle concentration and significant knockdown. The goal is to achieve the highest levels of knockdown to affect biomarkers and predict functional improvement, benchmarking back to preclinical data. The key criteria are concentration, knockdown, and the ability to dose escalate safely without safety signals.

Q: Has the FDA indicated any plans to hold an advisory committee meeting for the Amondys and Vyondys sNDAs, and do you see the recent Capricor AdCom as a negative read-through for these applications? A: Michael Severino (CEO) stated that the FDA has not indicated an intent to schedule an advisory committee for the Amondys and Vyondys reviews. Regarding the Capricor AdCom, he noted that the issues discussed were particular to Capricor's package and that Sarepta does not see a read-through to its programs. He emphasized that the sNDA applications are supported by clinical trial data and extensive real-world evidence, presenting a strong package for conversion to traditional approval.

Q: Regarding Cohort 8, is the ALI data all that's needed from the FDA to make a decision, and could the decision reinstate the non-ambulatory indication? A: Michael Severino (CEO) stated that the strategy is to complete Cohort 8 and approach the FDA with the 12-week data to discuss the regulatory path. He noted that the Cohort 8 data, together with other data sources like ENDEAVOR, could make a compelling argument for benefit-risk in the non-ambulatory population, but the exact path will be defined in discussions with regulators.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .